drugset / Trial / NCT02770378
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
Phase 1/2
Completed
10 enrolled
University of Ulm
Anticancer Fund, Belgium · collabReliable Cancer Therapies · collab
NaSingle-groupOpen-labelTreatment
Summary
A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma
Timeline
- Start
- 2016-11
- Primary completion
- 2018-10
- Completion
- 2020-12
Publications
- Cao Q, Hajosch A, Kast RE, Loehmann C, Hlavac M, Fischer-Posovszky P, Strobel H, Westhoff MA, Siegelin MD, Wirtz CR, Halatsch ME, Karpel-Massler G. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. Br J Cancer. 2024 May;130(8):1365-1376. doi: 10.1038/s41416-024-02608-8. Epub 2024 Feb 23.
- Halatsch ME, Dwucet A, Schmidt CJ, Muhlnickel J, Heiland T, Zeiler K, Siegelin MD, Kast RE, Karpel-Massler G. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals (Basel). 2021 Nov 29;14(12):1241. doi: 10.3390/ph14121241.
- Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, Taja-Chayeb L, Gonzalez-Fierro A, Garcia-Martinez E, Correa-Basurto J, Duenas-Gonzalez A. BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal. Curr Mol Pharmacol. 2022;15(6):815-831. doi: 10.2174/1874467214666211006123728.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Auranofin | Small molecule | 3 mg | Oral |
| Subject | Captopril | Small molecule | 50 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |
| Subject | Disulfiram | Small molecule | 250 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Minocycline | Small molecule | 100 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 400 mg | Oral |
| Subject | Sertraline | Small molecule | 100 mg | Oral |
| Subject | Temozolomide | Small molecule | 20 mg/m2 | — |